The global bleeding disorders market, valued at $13.78 billion in 2022, is poised for significant growth and is estimated to reach $25.97 billion by 2032, exhibiting a CAGR of 6.6% from 2023 to 2032.
This growth is driven by rapid advancements in bleeding disorder treatments, an increasing number of patients with hemophilia A, hemophilia B, and other bleeding disorders, and government initiatives to support hemophilia management.
Understanding Bleeding Disorders
Bleeding disorders encompass a group of conditions characterized by abnormal bleeding due to deficiencies or dysfunction in certain clotting factors in the blood.
These conditions result in impaired or absent clot formation, leading to abnormal or excessive bleeding. Hemophilia, a well-known bleeding disorder, predominantly affects males and can lead to life-threatening bleeding episodes. Another common bleeding disorder is Von Willebrand disease, affecting both males and females and causing prolonged bleeding following injury or surgery.
Key Drivers of Market Growth
Several factors are contributing to the growth of the bleeding disorders market, including:
Rapid advancements in bleeding disorder treatment.
An increasing number of patients with hemophilia A, hemophilia B, and other bleeding disorders.
Favorable government initiatives to support hemophilia management.
Rising awareness programs for bleeding disorder treatment.
Increased clinical trials for antihemophilic drugs.
A growing target population.
Improved diagnosis rates.
Surge in the use of prophylactic treatment for hemophilia.
Challenges and Opportunities
While the bleeding disorders market is on an upward trajectory, challenges include the high cost of hemophilia treatment and serious adverse effects associated with plasma-derived products. However, the market also presents opportunities, such as increased healthcare expenditure and unmet medical demands for improved hemophilia treatment options in developing countries.
The bleeding disorders market is segmented based on disease type, treatment type, distribution channel, and region:
Disease Type: Hemophilia A, Hemophilia B, Von Willebrand Disease, and Others.
Treatment Type: Factor Replacement Therapy (Recombinant Coagulation Factor Concentrates and Plasma-Derived Coagulation Factor Concentrates) and Drug Therapy (Desmopressin, Antifibrinolytics, Fibrin Sealant).
Distribution Channel: Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies.
Region: North America (U.S., Canada, Mexico), Europe (Germany, France, the UK, Italy, Spain, Switzerland, rest of Europe), Asia-Pacific (China, India, Japan, South Korea, Australia, rest of Asia-Pacific), and LAMEA (Brazil, South Africa, UAE, Argentina, rest of LAMEA).
Key Market Insights
Hemophilia A is the highest revenue contributor to the market and is expected to grow at a CAGR of 6.6% during the forecast period.
Factor replacement therapy is the highest revenue contributor to the market.
Hospital pharmacies are estimated to be the fastest-growing distribution channel.
North America holds a major share of the bleeding disorders market, while Asia-Pacific is expected to witness the highest CAGR.
Key Market Players
Leading companies in the bleeding disorders market include Medexus Pharma, Inc., Bayer AG, Novo Nordisk A/S, Grifols, S.A., Octapharma AG, Takeda Pharmaceutical Company Limited, CSL Limited, Pfizer Inc., Sanofi, and F. Hoffmann-La Roche Ltd.
Rise in Prevalence of Hemophilia
Technological Advancements in the Treatment of Hemophilia
Favorable Government Initiatives for Hemophilia Management
High Cost of Bleeding Disorders Treatments
Rise in Awareness About Bleeding Disorders in Developing Countries
About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Auna S.A. ("Auna," the "Company" or "we"), one of the largest players in the Latin American healthcare industry and with presence in Mexico, Colombia and Peru, announced today the early participation results of its previously announced offer to...
The camphor oil market size is expected to grow by USD 14,787.82 thousand from 2022 to 2027, according to Technavio. In addition, the growth momentum of the market will progress at a CAGR of 3.13% during the forecast period. Growing demand for...
Seelos Therapeutics, Inc. ("Seelos"), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it has priced its underwritten public offering of...
Chula Medicine has designed an anti-choke mug with calculated angle, amount, and time of water flow from the mug to the patient's lips hoping to reduce choking that may lead to lung infection, bring peace of mind to caregivers, and make it safer for...
Abstrax, the leader in botanical flavor technology, is thrilled to announce its partnership with Advanced Vapor Devices LLC (AVD), a leader in cannabis vaporizer technology, and McKinney Regulatory Science...
Thermo Fisher Scientific Inc. ("Thermo Fisher") announced today that it has priced an offering of $2.5 billion aggregate principal amount (the "Offering") of the following notes:
$1.0 billion aggregate principal amount of its 5.000% senior notes...